Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Evgen Pharma ( (GB:TCF) ) has issued an announcement.
TheraCryf plc, a UK biotechnology company developing treatments for addiction and other neuropsychiatric disorders, is advancing a pipeline led by a novel orexin-1 receptor antagonist aimed at binge eating, alcohol and substance use disorders. The group also pursues a dopamine transporter modulator for fatigue of brain origin and maintains a legacy oncology programme, leveraging a capital-light, virtual model that focuses on partnering after early clinical validation.
TheraCryf has filed a new process patent covering novel aspects of the manufacturing method for its lead orexin-1 receptor antagonist, Ox-1, which could secure up to 20 years of additional protection and extend commercial exclusivity beyond its existing composition of matter patent. The move strengthens the Ox-1 intellectual property estate, raises barriers to generic competition and is positioned as a key step in enhancing the programme’s long-term commercial value and attractiveness to potential partners as it moves toward clinical readiness later in 2026.
Spark’s Take on TCF Stock
According to Spark, TipRanks’ AI Analyst, TCF is a Neutral.
The score is held back primarily by weak financial performance (ongoing losses and cash burn despite a debt-free balance sheet). Technicals are moderately supportive due to price strength versus moving averages, but the very overbought RSI raises near-term risk. Valuation is constrained by negative earnings and no dividend support.
To see Spark’s full report on TCF stock, click here.
More about Evgen Pharma
TheraCryf plc is a UK-based biotechnology company focused on developing new medicines for addiction and other neuropsychiatric disorders, targeting areas of significant unmet need in central nervous system conditions. Its lead programme is a novel, best-in-class orexin-1 receptor antagonist for treating addiction, including binge eating, alcohol and other substance use disorders, supported by additional programmes in fatigue of brain origin and oncology, and run through a capital-light, virtual development model.
The company’s pipeline includes a dopamine transporter modulator aimed at fatigue associated with multiple sclerosis, chemotherapy and narcolepsy, alongside a legacy grant-funded glioblastoma oncology project with SFX-01. TheraCryf advances its assets to early clinical or proof-of-concept stages before seeking partnerships with larger pharmaceutical or biotechnology firms, operating from its headquarters at Alderley Park in Cheshire.
Average Trading Volume: 4,036,625
Technical Sentiment Signal: Sell
Current Market Cap: £4.84M
See more insights into TCF stock on TipRanks’ Stock Analysis page.